+
Abarbanel
J, Benet
AE, Lask
D,
et al. Sports hematuria. J Urol. 1990; 143:887–890.
+
Abrams
CS Acquired qualitative platelet disorders. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams Hematology. 7th ed. New York: McGraw-Hill; 2006:1833–1855.
+
Alcindor
T, Bridges
KR Sideroblastic anaemias. Br J Haematol. 2002;116:733–743.
+
Almenoff
J, Tonning
JM, Gould
AL,
et al. Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf. 2005; 28:981–1007.
+
Altucci
L, Clarke
N, Nebbioso
A,
et al. Acute myeloid leukemia: therapeutic impact of epigenetic drugs. Int J Biochem Cell Biol. 2005; 37:1752–1762.
+
Ananyeva
NM, Lacroix-Desmazes
S, Hauser
CA,
et al. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis. 2004; 15:109–124.
+
Andersen
RL, Bagby
GC
Jr, Richert-Boe
K Therapy-related preleukemic syndrome. Cancer. 1981; 47:1867–1871.
+
Andres
E, Kurtz
JE, Martin-Hunyadi
C,
et al. Nonchemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte colony-stimulating factor. Am J Med. 2002; 112:460–464.
+
Andres
E, Maloisel
F, Zimmer
J The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis. Br J Haematol. 2010;150(1):3–8.
+
Ansell
J, Hirsh
J, Poller
L,
et al. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:204S–233S.
+
Arndt
PA, Garratty
G The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol. 2005; 42:137–144.
+
Arneborn
P, Palmblad
J Drug-induced neutropenia—a survey for Stockholm 1973–1978. Acta Med Scand. 1982; 212:289–292.
+
Aster
RH Drug-induced immune cytopenias. Toxicology. 2005;209: 149–153.
+
Aster
RH, Bougie
DW Drug-induced immune thrombocytopenia. N Engl J Med. 2007; 357:580–587.
+
Aster
RH, Curtis
BR, McFarland
JG,
et al. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis and management. J Thromb Haemost. 2009; 7:911–918.
+
Athens
JW, Haab
OP, Raab
SO,
et al. Leukokinetic studies. IV. The total blood, circulating and marginal granulocyte pools and the granulocyte turnover rate in normal subjects. J Clin Invest. 1961; 40:989–995.
+
Babior
BM Folate, cobalamin, and myeloblastic anemias. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams Hematology. 7th ed. New York: McGraw-Hill; 2006:477–509.
+
Babior
BM, Golde
DW Production, distribution and fate of neutrophils. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology. 5th ed. New York: McGraw-Hill; 1995:773–779.
+
Bahrami
S, Malone
JC, Webb
KG,
et al. Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis. Arch Dermatol. 2006; 142:155–161.
+
Baker
KR Hemolytic anemia resulting from physical injury to red cells. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams Hematology. New York: McGraw-Hill; 2006:709–716.
+
Barnes
PJ Corticosteroids: the drugs to beat. Eur J Pharmacol. 2006;533: 2–14.
+
Bates
SM, Greer
IA, Hirsh
J,
et al. Use of antithrombotic agents during pregnancy: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:627S–644S.
+
Bench
AJ, Nacheva
EP, Champion
KM,
et al. Molecular genetics and cytogenetics of myeloproliferative disorders. Baillieres Clin Haematol. 1998; 11:819–848.
+
Bennett
A, Sanger
GJ Pinane thromboxane A2 analogues are non-selective prostanoid antagonists in rat and human stomach muscle. Br J Pharmacol. 1982; 77:591–596.
+
Bennett
CL, Luminari
S, Nissenson
AR,
et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004; 351:1403–1408.
+
Bennett
JM, Catovsky
D, Daniel
MT,
et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann Intern Med. 1985;103: 620–625.
+
Bergsagel
DE, Wong
O, Bergsagel
PL,
et al. Benzene and multiple myeloma: appraisal of the scientific evidence. Blood. 1999; 94:1174–1182.
+
Berkowitz
FE Hemolysis and infection: categories and mechanisms of their interrelationship. Rev Infect Dis. 1991; 13:1151–1162.
+
Berliner
N, Horwitz
M, Loughran
TP
Jr Congenital and acquired neutropenia. In: Broudy VC, Berliner N, Larson RA, Leung LL, eds. American Society of Hematology Education Program Book. Washington, DC: American Society of Hematology; 2004:63–79.
+
Berry
RG, Morrison
JA, Watts
JW,
et al. Surreptitious superwarfarin ingestion with brodifacoum. South Med J. 2000; 93:74–75.
+
Bertolaccini
ML, Hughes
GR, Khamashta
MA Revisiting antiphospholipid antibodies: from targeting phospholipids to phospholipid binding proteins. Clin Lab. 2004; 50:653–665.
+
Beutler
E G6PD: population genetics and clinical manifestations. Blood Rev. 1996; 10:45–52.
+
Beutler
E Hemolytic anemias resulting from infections with microorganisms. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams Hematology. 7th ed. New York: McGraw-Hill; 2006a:723–727.
+
Beutler
E Hemolytic anemias resulting from chemical and physical agents. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams Hematology. 7th ed. New York: McGraw-Hill; 2006b:717–721.
+
Beutler
E Hereditary and acquired sideroblastic anemias. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams Hematology. 7th ed. New York: McGraw-Hill; 2006c:823–828.
+
Bitter
MA, Le Beau
MM, Rowley
JD,
et al. Associations between morphology, karyotype, and clinical features in myeloid leukemias. Hum Pathol. 1987; 18:211–225.
+
Bloom
JC Principles of hematotoxicology: laboratory assessment and interpretation of data. Toxicol Pathol. 1993; 21:130–134.
+
Bloom
JC, Lewis
HB, Sellers
TS,
et al. The hematopathology of cefonicid- and cefazedone-induced blood dyscrasias in the dog. Toxicol Appl Pharmacol. 1987; 90:143–155.
+
Blossom
D, Kallen
A, Patel
PR,
et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med. 2008; 359:2674–2684.
+
Borregaard
N, Boxer
LA Disorders of neutrophil function. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams Hematology. 7th ed. New York: McGraw-Hill; 2006: 921–957.
+
Bradberry
SM Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue. Toxicol Rev. 2003; 22:13–27.
+
Bradberry
SM, Aw
TC, Williams
NR,
et al. Occupational methaemoglobinaemia. Occup Environ Med. 2001; 58:611–615.
+
Brayton
RG, Stokes
PE, Schwartz
MS,
et al. Effect of alcohol and various diseases on leukocyte mobilization, phagocytosis and intracellular bacterial killing. N Engl J Med. 1970; 282:123–128.
+
Browning
E Toxicity and Metabolism of Industrial Solvents. London: Elsevier; 1965.
+
Broxmeyer
HE, Orschell
CM, Clapp
DW,
et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005; 201:1307–1318.
+
Capsoni
F, Sarzi-Puttini
P, Zanella
A Primary and secondary autoimmune neutropenia. Arthritis Res Ther. 2005; 7:208–214.
+
Caramori
G, Adcock
I Anti-inflammatory mechanisms of glucocorticoids targeting granulocytes. Curr Drug Targets Inflamm Allergy. 2005; 4:455–463.
+
Cartwright
GE, Athens
JW, Wintrobe
MM The kinetics of granulopoiesis in normal man. Blood. 1964; 24:780–803.
+
Carver
JH, Hatch
FT, Branscomb
EW Estimating maximum limits to mutagenic potency from cytotoxic potency. Nature. 1979; 279:154–156.
+
Casciato
DA, Scott
JL Acute leukemia following prolonged cytotoxic agent therapy. Medicine. 1979; 58:32–47.
+
Cazzola
M, Invernizzi
R, Bergamaschi
G,
et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood. 2003; 101:1996–2000.
+
Cerulli
J, Grabe
DW, Gauthier
I,
et al. Chromium picolinate toxicity. Ann Pharmacother. 1998; 32:428–431.
+
Cesar
JM, de Miguel
D, Garcia
AA,
et al. Platelet dysfunction in primary thrombocythemia using the platelet function analyzer, PFA-100. Am J Clin Pathol. 2005; 123:772–777.
+
Chabner
BA, Wilson
W, Supko
J Pharmacology and toxicity of antineoplastic drugs. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams Hematology. 7th ed. New York: McGraw-Hill; 2006:247–274.
+
Chakraverty
R, Davidson
S, Peggs
K,
et al. The incidence and cause of coagulopathies in an intensive care population. Br J Haematol. 1996; 93:460–463.
+
Chriswell
KA, Bleavins
MR, Zeilinski
D,
et al. Comparison of flow cytometric and manual bone marrow differentials in Wistar rats. Cytometry. 1998a;32:9–17.
+
Chriswell
KA, Bleavins
MR, Zeilinski
D,
et al. Flow cytometric evaluation of bone marrow differentials in rats with pharmacologically induced hematologic abnormalities. Cytometry. 1998b;32:18–27.
+
Chriswell
KA, Sulkanen
AP, Hochbaum
AF,
et al. Effects of phenylhydrazine or phlebotomy on peripheral blood, bone marrow and erythropoietin in Wistar rats. J Appl Toxicol. 2000; 20:25–34.
+
Chua
JD, Friedenberg
WR Superwarfarin poisoning. Arch Intern Med. 1998; 158:1929–1932.
+
Clifton
J, Leikin
JB Methylene blue. Am J Ther. 2003; 10:289–291.
+
Coleman
MD, Coleman
NA Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf. 1996; 14:394–405.
+
Collen
D, Lijnen
HR Thrombolytic agents. Thromb Haemost. 2005;93: 627–630.
+
Contrino
J, Marucha
P, Ribaudo
R,
et al. Effects of mercury on human polymorphonuclear leukocyte function in vitro. Am J Pathol. 1988;132: 110–118.
+
Cummings
TF The treatment of cyanide poisoning. Occup Med. 2004; 54:82–85.
+
Cuneo
A, Fagioli
F, Pazzi
I,
et al. Morphologic, immunologic and cytogenetic studies in acute myeloid leukemia following occupational exposure to pesticides and organic solvents. Leuk Res. 1992; 16:789–796.
+
Cunningham
JL, Leyland
MJ, Delamore
IW,
et al. Acetanilide oxidation in phenylbutazone-associated hypoplastic anaemia. Br Med J. 1974; 3:313–317.
+
Curzen
N, Haque
R, Timmis
A Applications of thrombolytic therapy. Intensive Care Med. 1998; 24:756–768.
+
Custer
RP, Ahlfeldt
FE Studies on the structure and function of bone marrow. J Lab Clin Med. 1932; 17:960–962.
+
Dahl
OE, Garvik
LJ, Lyberg
T Toxic effects of methylmethacrylate monomer on leukocytes and endothelial cells in vitro. Acta Orthop Scand. 1994; 65:147–153.
+
Dale
DC Neutropenia and neutrophilia. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams Hematology. 7th ed. New York: McGraw-Hill; 2006:907–955.
+
D’Andrea
G, Ambrosio
RL, Perna
P,
et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005; 105:645–649.
+
Davoren
A, Aster
RH Heparin-induced thrombocytopenia and thrombosis. Am J Hematol. 2006; 81:36–44.
+
De Clercq
E Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100. Mini Rev Med Chem. 2005; 5:805–824.
+
de Latour
RP, Visconte
V, Takaku
T,
et al. Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood. 2010;116: 4175–4180.
+
Deckmyn
H, Vanhoorelbeke
K, Peerlinck
K Inhibitory and activating human antiplatelet antibodies. Baillieres Clin Haematol. 1998; 11:343–359.
+
Deldar
A Drug-induced blood disorders: review of pathogenetic mechanisms and utilization of bone marrow cell culture technology as an investigative approach. Curr Topics Vet Res. 1994; 1:83–101.
+
Deldar
A, Parchment
RE Preclinical risk assessment for hematotoxicity: animal models and in vitro systems. In: Sipes IG MAGA, ed. Comprehensive Toxicology. Oxford: Pergamon Press; 1997:321–333.
+
Deldar
A, Stevens
CE Development and application of in vitro models of hematopoiesis to drug development. Toxicol Pathol. 1993; 21:231–240.
+
Delvaeye
M, Noris
M, de Vriese
A,
et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361: 345–357.
+
Demirer
T, Bensinger
WI Optimization of peripheral blood stem cell collection. Curr Opin Hematol. 1995; 2:219–226.
+
Dessypris
EN Erythropoiesis. In: Lee CR, Foerster J, Lukens J, Paraskevas P, Greer JP, Rodgers GM, eds. Wintrobe’s Clinical Hematology. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 1999:169–192.
+
Dieckhaus
CM, Thompson
CD, Roller
SG,
et al. Mechanisms of idiosyncratic drug reactions: the case of felbamate. Chem Biol Interact. 2002;142: 99–117.
+
Dinwoodey
DL, Ansell
JE Heparins, low-molecular-weight heparins, and pentasaccharides. Clin Geriatr Med. 2006; 22:1–15, vii.
+
Djaldetti
M, Blay
A, Bergman
M,
et al. Pure red cell aplasia—a rare disease with multiple causes. Biomed Pharmacother. 2003; 57:326–332.
+
Dreno
B, Trossaert
M, Boiteau
HL,
et al. Zinc salts effects on granulocyte zinc concentration and chemotaxis in acne patients. Acta Derm Venereol. 1992; 72:250–252.
+
Du
DL, Volpe
DA, Grieshaber
CK,
et al. Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro. Invest New Drugs. 1991; 9:149–157.
+
Edwards
IR, Lindquist
M, Wiholm
BE,
et al. Quality criteria for early signals of possible adverse drug reactions. Lancet. 1990; 336:156–158.
+
Eramo
A, Lotti
F, Sette
G,
et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008; 15:504–514.
+
Erickson-Miller
CL, May
RD, Tomaszewski
J,
et al. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol. 1997; 39:467–472.
+
European Medicines Agency, Committee for Proprietary Medicinal Products. Notes for Guidance of Immunotoxicity Studies for Human Pharmaceuticals. London: European Medicines Agency; 2006:1–9.
+
Fagioli
F, Cuneo
A, Piva
N,
et al. Distinct cytogenetic and clinicopathologic features in acute myeloid leukemia after occupational exposure to pesticides and organic solvents. Cancer. 1992; 70:77–85.
+
Fan
F, Wood
KV Bioluminescent aasays for high-throughput screening. Assay Drug Dev Technol. 2007; 5:127–136.
+
Feldman
BF, Zinkle
JG, Jain
NC, eds. Schalm’s Veterinary Hematology. 5th ed. Ames, IA: Blackwell Publishing; 2006.
+
Fisch
P, Handgretinger
R, Schaefer
HE Pure red cell aplasia. Br J Haematol. 2000; 111:1010–1022.
+
Fiske
DN, McCoy
HE
III, Kitchens
CS Zinc-induced sideroblastic anemia: report of a case, review of the literature, and description of the hematologic syndrome. Am J Hematol. 1994; 46:147–150.
+
Flieder
DB, Travis
WD Pathologic characteristics of drug-induced lung disease. Clin Chest Med. 2004; 25:37–45.
+
Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research. S8 immunotoxicity studies for human pharmaceuticals. In: Guidance for Industry. Rockville, MD: Food and Drug Administration; 2006:1–13.
+
Foucar
K, McKenna
RW, Bloomfield
CD,
et al. Therapy-related leukemia: a panmyelosis. Cancer. 1979; 43:1285–1296.
+
Frazier
JM In vitro toxicity testing: applications to safety evaluation. In: Frazier JM, ed. In Vitro Toxicity Testing Applications to Safety Evaluation. New York: Marcel Dekker; 1992:5–7.
+
Friberg
LE, Karlsson
MO Mechanistic models for myelosuppression. Invest New Drugs. 2003; 21:183–194.
+
Frickhofen
N, Liu
JM, Young
NS Etiologic mechanisms of hematopoietic failure. Am J Pediatr Hematol Oncol. 1990; 12:385–395.
+
Furlan
M, Robles
R, Galbusera
M,
et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998; 339:1578–1584.
+
Gallardo
S, Cardaba
B, Posada
M,
et al. Toxic oil syndrome: genetic restriction and immunomodulatory effects due to adulterated oils in a model of HLA transgenic mice. Toxicol Lett. 2005; 159:173–181.
+
Gamazon
ER, Im
HK, O’Donnell
PF,
et al. Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity. Mol Cancer Ther. 2011;10(3):472–480.
+
Garb
E Non-chemotherapy drug-induced agranulocytosis. Expert Opin Drug Saf. 2007;6(3):323–335.
+
Gerson
SL, Meltzer
H Mechanisms of clozapine-induced agranulocytosis. Drug Saf. 1992;7(suppl 1):17–25.
+
Gerson
WT, Fine
DG, Spielberg
SP,
et al. Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood. 1983; 61:889–893.
+
Girard
D Activation of human polymorphonuclear neutrophils by environmental contaminants. Rev Environ Health. 2003; 18:75–89.
+
Godley
LA, Larson
RA The syndrome of therapy-related myelodysplasia and myeloid leukemia. In: Bennett JM, ed. The Myelodysplastic Syndromes: Pathobiology and Clinical Management. New York: Dekker; 2001:139–176.
+
Golden
R, Pyatt
D, Shields
PG Formaldehyde as a potential human leukemogen: an assessment of biological plausibility. Crit Rev Toxicol. 2006; 36:135–153.
+
Golomb
HM, Alimena
G, Rowley
JD,
et al. Correlation of occupation and karyotype in adults with acute nonlymphocytic leukemia. Blood. 1982; 60:404–411.
+
Gonzalez
H, Leblond
V, Azar
N,
et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther. 1998; 40:113–118.
+
Grant
C, Wilson
WH, Dunleavy
K Neutropenia associated with rituximab therapy. Curr Opin Hematol. 2011;18(1):49–54.
+
Greene
MH, Harris
EL, Gershenson
DM,
et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med. 1986; 105:360–367.
+
Guevara
A, Labarca
J, Gonzalez-Martin
G Heparin-induced transaminase elevations: a prospective study. Int J Clin Pharmacol Ther Toxicol. 1993; 31:137–141.
+
Hagen
EC, Ballieux
BE, van Es
LA,
et al. Antineutrophil cytoplasmic autoantibodies: a review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences. Blood. 1993; 81:1996–2002.
+
Hajjar
A Fibrinolysis and thrombolysis. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams Hematology. 7th ed. New York: McGraw-Hill; 2006:1833–1855.
+
Hall
RL Clinical pathology for preclinical safety assessment: current global guidelines. Toxicol Pathol. 1992; 20:472–476.
+
Hall
RL Evaluation and interpretation of hematologic data in preclinical toxicology. In: Sipes IG, McQueen AC, Gandolfi AJ, eds. Comprehensive Toxicology. Oxford: Pergamon Press; 1997:321–333.
+
Hanahan
D, Weinberg
R Hallmarks of cancer: the next generation. Cell. 2011; 144:646–674.
+
Harder
S, Thurmann
P Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet. 1996; 30:416–444.
+
Harrison
DE, Lerner
CP Most primitive hematopoietic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. Blood. 1991; 78:1237–1240.
+
Hatherill
JR, Till
GO, Bruner
LH,
et al. Thermal injury, intravascular hemolysis, and toxic oxygen products. J Clin Invest. 1986; 78:629–636.
+
Heissig
B, Ohki
Y, Sato
Y,
et al. A role for niches in hematopoietic cell development. Hematology. 2005; 10:247–253.
+
Hincks
I, Woodcock
BE, Thachil
J Is rituximab-induced late-onset neutropenia a good prognostic indicator in lymphoproliferative disorders? Br J Haematol. 2011; 153:402–416.
+
Hirsh
J, Raschke
R Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:188S–203S.
+
Hoffmann
MJ, Sinko
PJ, Lee
YH,
et al. Pharmacokinetic studies in Tg.AC and FVB mice administered [14C] benzene either by oral gavage or intradermal injection. Toxicol Appl Pharmacol. 2001; 174:139–145.
+
Honigfeld
G, Arellano
F, Sethi
J,
et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59(suppl 3):3–7.
+
Horikoshi
A, Murphy
MJ
Jr Comparative effects of chemotherapeutic drugs on human and murine hematopoietic progenitors in vitro. Chemotherapy. 1982; 28:480–501.
+
Horn
TL, Harder
JB, Johnson
WD,
et al. Integration of in vivo and in vitro approaches to characterize the toxicity of antalarmin, a corticotropin-releasing hormone receptor antagonist. Toxicology. 2008; 248:8–17.
+
Hsia
CC Respiratory function of hemoglobin. N Engl J Med. 1998; 338:239–247.
+
Huang
RS, Kistner
EO, Bleibel
WK,
et al. Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther. 2007;6(1):31–36.
+
Hudson
G Bone-marrow volume in the human foetus and newborn. Br J Haematol. 2006; 11:446–452.
+
Hunter
FT Chronic exposure of benzene. II. The clinical effects. J Ind Hyg Toxicol. 1939; 21:331–354.
+
Huxtable
LM, Tafreshi
MJ, Rakkar
AN Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol. 2006; 97:426–429.
+
Ibanez
L, Vidal
X, Ballarin
E,
et al. Population-based drug-induced agranulocytosis. Arch Int Med. 2005;165(8):869–874.
+
ICH. Note for guidance on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals. Fed Reg. 2000.
+
ICH. Safety pharmacology studies for human pharmaceuticals. Fed Reg. 2001; 66:36791–36792.
+
Irons
RD Leukemogenesis as a toxic response. In: Sipes IG, McQueen AC, Gandolfi AJ, eds. Comprehensive Toxicology. Oxford: Pergamon Press; 1997:175–199.
+
Jaffe
ES World Health Organization Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues Pathology and Genetics. Lyon: IARC Press; 2001.
+
Jandl
JH Blood. Boston: Little Brown & Co; 1987.
+
Johansson
B, Mertens
F, Heim
S,
et al. Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL). Eur J Haematol. 1991; 47:17–27.
+
Julia
A, Olona
M, Bueno
J,
et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol. 1991; 79:366–371.
+
Jurk
K, Kehrel
BE Platelets: physiology and biochemistry. Semin Thromb Hemost. 2005; 31:381–392.
+
Kantarjian
HM, Keating
MJ, Walters
RS,
et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986; 4:1748–1757.
+
Kao
LW, Nanagas
KA sCarbon monoxide poisoning. Med Clin North Am. 2005; 89:1161–1194.
+
Kaushansky
K Lineage-specific hematopoietic growth factors. N Engl J Med. 2006; 354:2034–2045.
+
Keng
PC Use of flow cytometry in the measurement of cell mitotic cycle. Int J Cell Cloning. 1986; 4:295–311.
+
Khan
NA, Kruse
JA Methemoglobinemia induced by topical anesthesia: a case report and review. Am J Med Sci. 1999; 318:415–418.
+
Kilbourne
EM, Paz
M, Abaitua
B,
I,
et al. Toxic oil syndrome: a current clinical and epidemiologic summary, including comparisons with the eosinophilia–myalgia syndrome. J Am Coll Cardiol. 1991; 18:711–717.
+
Kim-Shapiro
DB, Gladwin
MT, Patel
RP,
et al. The reaction between nitrite and hemoglobin: the role of nitrite in hemoglobin-mediated hypoxic vasodilation. J Inorg Biochem. 2005; 99:237–246.
+
Kolachana
P, Subrahmanyam
VV, Meyer
KB,
et al. Benzene and its phenolic metabolites produce oxidative DNA damage in HL60 cells in vitro and in the bone marrow in vivo. Cancer Res. 1993;53: 1023–1026.
+
Koren
E, Zuckerman
LA, Mire-Sluis
AR Immune responses to therapeutic proteins in humans—clinical significance, assessment and prediction. Curr Pharm Biotechnol. 2002; 3:349–360.
+
Kuderer
NM, Cosler
L, Crawford
J Cost and mortality associated with febrile neutropenia in adult cancer patients. Proc Am Soc Clin Oncol. 2002;21:250a.
+
Kumar
S, Bandyopadhyay
U Free heme toxicity and its detoxification systems in human. Toxicol Lett. 2005; 157:175–188.
+
Ladiges
WC, Storb
R, Thomas
ED Canine models of bone marrow transplantation. Lab Anim Sci. 1990; 40:11–15.
+
Lane
DA, Philippou
H, Huntington
JA Directing thrombin. Blood. 2005; 106:2605–2612.
+
Larochelle
A, Krouse
A, Metzger
M,
et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood. 2006; 107:3772–3778.
+
Larson
RA, Le Beau
MM Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem Biol Interact. 2005;153–154: 187–195.
+
Lataillade
JJ, Domenech
J, Le Bousse-Kerdiles
MC Stromal cell-derived factor-1 (SDF-1)\CXCR4 couple plays multiple roles on haematopoietic progenitors at the border between the old cytokine and new chemokine worlds: survival, cell cycling and trafficking. Eur Cytokine Netw. 2004; 15:177–188.
+
Laurence
AD Location, movement and survival: the role of chemokines in haematopoiesis and malignancy. Br J Haematol. 2006; 132:255–267.
+
Le Beau
MM, Albain
KS, Larson
RA,
et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol. 1986;4: 325–345.
+
Leung
KN, Mak
NK, Fung
MC Cytokines in the differentiation therapy of leukemia: from laboratory investigations to clinical applications. Crit Rev Clin Lab Sci. 2005; 42:473–514.
+
Levine
EG, Bloomfield
CD Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol. 1992; 19:47–84.
+
Levine
JG, Szarfman
A Standardized data structures and visualization tools: a way to accelerate the regulatory review of the integrated summary of safety of new drug applications. Biopharm Rep. 1996; 4:12–17.
+
Li
J, Yang
C, Xia
Y,
et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001; 98:3241–3248.
+
Li
R A hypothesis that explains the heterogeneity of drug-induced immune thrombocytopenia. Blood. 2010;115:914.
+
Lian
EC Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond. Semin Thromb Hemost. 2005; 31:625–632.
+
Liesveld
JL, Lichtman
MA Evaluation of granulocytes and mononuclear phagocytes. In: Sipes IG, McQueen CA, Gandolfi AJ, eds. Comprehensive Toxicology. Oxford: Pergamon Press; 1997:123–144.
+
Liles
WC, Rodger
E, Broxmeyer
HE,
et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion. 2005; 45:295–300.
+
Lillevang
ST, Albertsen
M, Rasmussen
F,
et al. Effect of radiographic contrast media on granulocyte phagocytosis of Escherichia coli in a whole blood flow cytometric assay. Invest Radiol. 1994; 29:68–71.
+
Lindorfer
MA, Hahn
CS, Foley
PL,
et al. Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1: mechanisms and applications. Immunol Rev. 2001; 183:10–24.
+
Lollar
P Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J Thromb Haemost. 2004; 2:1082–1095.
+
Lollar
P Pathogenic antibodies to coagulation factors. Part II. Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor. J Thromb Haemost. 2005; 3:1385–1391.
+
Look
AT Molecular pathogenesis of MDS. In: Berliner N, Lee SJ, Linenberger M, Vogelsang GB, eds. American Society of Hematology Education Program Book. Washington, DC: American Society of Hematology; 2005:156–160.
+
Loomis
MR, Henrickson
RV, Anderson
JH Effects of ketamine hydrochloride on the hemogram of rhesus monkeys (Macaca mulatta). Lab Anim Sci. 1980; 30:851–853.
+
Lund
JE Toxicologic effects on blood and bone marrow. In: Feldman BF, Zinkl JG, Jain NC, eds. Schalm’s Veterinary Hematology. 5th ed. Ames, IA: Blackwell Publishing; 2000:44–50.
+
Lundberg
JO, Weitzberg
E NO generation from nitrite and its role in vascular control. Arterioscler Thromb Vasc Biol. 2005; 25:915–922.
+
Madison
FW, Squier
T The etiology of primary granulocytopenia (agranulocytic angina). J Am Med Assoc. 1934; 102:755–763.
+
Mangano
DT, Tudor
IC, Dietzel
C The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006; 354:353–365.
+
Mannucci
PM Hemostatic drugs. N Engl J Med. 1998; 339:245–253.
+
Marsh
JC Correlation of hematologic toxicity of antineoplastic agents with their effects on bone marrow stem cells: interspecies studies using an in vivo assay. Exp Hematol. 1985;13(suppl 16):16–22.
+
Martin
C, Burdon
PC, Bridger
G,
et al. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity. 2003; 19:583–593.
+
Mason
RP, Fischer
V Possible role of free radical formation in drug-induced agranulocytosis. Drug Saf. 1992;7(suppl 1):45–50.
+
Masubuchi
N Risk assessment of human myelotoxicity of anticancer drugs: a predictive model and the in vitro colony forming unit granulocyte/ macrophage (CFU-GM) assay. Pharmazie. 2006; 61:135–139.
+
Matzdorff
A Platelet function tests and flow cytometry to monitor antiplatelet therapy. Semin Thromb Hemost. 2005; 31:393–399.
+
Mauritzson
N, Johansson
B, Albin
M,
et al. Survival time in a population-based consecutive series of adult acute myeloid leukemia—the prognostic impact of karyotype during the time period 1976–1993. Leukemia. 2000; 14:1039–1043.
+
Mazzone
A, Mazzucchelli
I, Fossati
G,
et al. Granulocyte defects and opioid receptors in chronic exposure to heroin or methadone in humans. Int J Immunopharmacol. 1994; 16:959–967.
+
McMullin
MF, Buckley
O, Magill
MK,
et al. Long-term bone marrow culture profiles in patients with myelodysplastic syndromes are not explicable by defective apoptosis. Leuk Res. 1998; 22:735–740.
+
McRedmond
JP, Harriott
P, Walker
B,
et al. Streptokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1. Blood. 2000; 95:1301–1308.
+
Menon
V, Harrington
RA, Hochman
JS,
et al. Thrombolysis and adjunctive therapy in acute myocardial infarction: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:549S–575S.
+
Mitelman
F, Brandt
L, Nilsson
PG Relation among occupational exposure to potential mutagenic/carcinogenic agents, clinical findings, and bone marrow chromosomes in acute nonlymphocytic leukemia. Blood. 1978; 52:1229–1237.
+
Mitelman
F, Nilsson
PG, Brandt
L,
et al. Chromosome pattern, occupation, and clinical features in patients with acute nonlymphocytic leukemia. Cancer Genet Cytogenet. 1981; 4:197–214.
+
Miyagi
T, Lam
KM, Chuang
LF,
et al. Suppression of chemokine-induced chemotaxis of monkey neutrophils and monocytes by chlorinated hydrocarbon insecticides. In Vivo. 1998; 12:441–446.
+
Moeschlin
S, Wagner
K Agranulocytosis due to the occurrence of leukocyte-agglutinin; pyramidon and cold agglutinins. Acta Haematol. 1952; 8:29–41.
+
Monroe
DM, Hoffman
M What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol. 2005; 25:2463–2469.
+
Moore
DM Hematology of the mouse. In: Feldman BF, Zinkl JG, Jain NC, eds. Schalm’s Veterinary Hematology. 5th ed. Ames, IA: Blackwell Publishing; 2000a:1219–1224.
+
Moore
DM Hematology of the rat. In: Feldman BF, Zinkl JG, Jain NC, eds. Schalm’s Veterinary Hematology. 5th ed. Ames, IA: Blackwell Publishing; 2000b:1210–1218.
+
Moore
EE, Johnson
JL, Cheng
AM,
et al. Insights from studies of blood substitutes in trauma. Shock. 2005; 24:197–205.
+
Moore
MAS Embryologic and phylogenetic development of the haematopoietic system. Adv Biosci. 1975; 16:87–103.
+
Murphy
SB Secondary acute myeloid leukemia following treatment with epipodophyllotoxins. J Clin Oncol. 1993; 11:199–201.
+
Nakagawa
M, Terashima
T, D’yachkova
Y,
et al. Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation. 1998; 98:2307–2313.
+
Napier
I, Ponka
P, Richardson
DR Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood. 2005; 105:1867–1874.
+
Nathan
C Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 2006; 6:173–182.
+
Naughton
BA, Sibanda
B, Azar
L,
et al. Differential effects of drugs upon hematopoiesis can be assessed in long-term bone marrow cultures established on nylon screens. Proc Soc Exp Biol Med. 1992;199: 481–490.
+
Negro
GD, Bonato
M, Gribaldo
L In vitro bone marrow granulocyte-macrophage progenitor cultures in the assessment of hematotoxic potential of the new drugs. Cell Biol Toxicol. 2001; 17:95–105.
+
Nguyen
ST, Cabrales
RE, Bashour
CA,
et al. Benzocaine-induced methemoglobinemia. Anesth Analg. 2000; 90:369–371.
+
Nifli
AP, Notas
G, Mamoulaki
M,
et al. Comparison of a multiplex, bead-based fluorescent assay and immunofluorescence methods for the detection of ANA and ANCA autoantibodies in human serum. J Immunol Methods. 2006; 311:189–197.
+
Njalsson
R, Norgren
S Physiological and pathological aspects of GSH metabolism. Acta Paediatr. 2005; 94:132–137.
+
Olson
H, Betton
G, Robinson
D,
et al. Concordance of the toxicity of pharmaceuticals in humans and animals. Regul Toxicol Pharmacol. 2000; 32:56–67.
+
O’Neill
R Assessment of safety. In: Peace KE, ed. Biopharmaceutical Statistics for Drug Development. New York: Marcel Dekker; 1988:543–604.
+
Palmblad
J, Papadaki
HA, Eliopoulos
G Acute and chronic neutropenias. What is new? J Intern Med. 2001; 250:476–491.
+
Papassotiriou
I, Kister
J, Griffon
N,
et al. Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators. Br J Haematol. 1998; 102:1165–1171.
+
Parchment
RE, Huang
M, Erickson-Miller
CL Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicol Pathol. 1993; 21:241–250.
+
Parchment
RE, Murphy
MJ Human hematopoietic stem cells: laboratory assessment and response to toxic injury. In: Sipes IG MAGA, ed. Comprehensive Toxicology. Oxford: Pergamon Press; 1997:303–320.
+
Parent-Massin
D, Thouvenot
D, Rio
B,
et al. Lindane haematotoxicity confirmed by in vitro tests on human and rat progenitors. Hum Exp Toxicol. 1994; 13:103–106.
+
Patton
WN, Duffull
SB Idiosyncratic drug-induced haematological abnormalities. Incidence, pathogenesis, management and avoidance. Drug Saf. 1994; 11:445–462.
+
Pedersen-Bjergaard
J, Pedersen
M, Roulston
D,
et al. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 1995; 86:3542–3552.
+
Pedersen-Bjergaard
J, Philip
P, Pedersen
NT,
et al. Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. II. Bone marrow cytology, cytogenetics, results of HLA typing, response to antileukemic chemotherapy, and survival in a total series of 55 patients. Cancer. 1984; 54:452–462.
+
Perazella
MA, Biswas
P Acute hyperkalemia associated with intravenous epsilon-aminocaproic acid therapy. Am J Kidney Dis. 1999; 33:782–785.
+
Percy
MJ, McFerran
NV, Lappin
TR Disorders of oxidised haemoglobin. Blood Rev. 2005; 19:61–68.
+
Pessina
A, Albella
B, Bayo
M,
et al. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol Sci. 2003; 75:355–367.
+
Pessina
A, Albella
B, Bueren
J,
et al. Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. Toxicol In Vitro. 2001; 15:729–740.
+
Pessina
A, Malerba
I, Gribaldo
L Hematotoxicity testing by cell clonogenic assay in drug development and preclinical trials. Curr Pharm Des. 2005; 11:1055–1065.
+
Peters
DC, Noble
S Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs. 1999; 57:233–260.
+
Peters
WP, Holland
JF, Senn
H,
et al. Corticosteroid administration and localized leukocyte mobilization in man. N Engl J Med. 1972; 286:342–345.
+
Peterson
JA, Nelson
TN, Kanack
AJ,
et al. Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA. Blood. 2008; 111:1234–1239.
+
Phillips
GL The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Semin Oncol. 2002; 29:53–56.
+
Pisciotta
AV Immune and toxic mechanisms in drug-induced agranulocytosis. Semin Hematol. 1973; 10:279–310.
+
Pisciotta
AV Response of granulocytes to toxic injury. In: Sipes IG, McQueen AC, Gandolfi AJ, eds. Comprehensive Toxicology. Oxford: Pergamon Press; 1997:145–158.
+
Platanias
LC Abnormalities in Th 17 cells in aplastic anemia. Blood. 2010; 116:4039–4040.
+
Ponka
P Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood. 1997; 89:1–25.
+
Powley
MW, Carlson
GP sHepatic and pulmonary microsomal benzene metabolism in CYP2E1 knockout mice. Toxicology. 2001; 169:187–194.
+
Poyart
C, Marden
MC, Kister
J Bezafibrate derivatives as potent effectors of hemoglobin. Methods Enzymol. 1994; 232:496–513.
+
Prchal
JT Clinical manifestations and classification of erythrocyte disorders. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams Hematology. 7th ed. New York: McGraw-Hill; 2006:411–418.
+
Preiss
BS, Bergman
OJ, Friis
LS,
et al. Cytogenetic findings in adult secondary acute myeloid leukemia (AML): frequency of favorable and adverse chromosomal aberrations do not differ from adult de novo AML. Cancer Genet Cytogenet. 2010; 202:108–122.
+
Pyatt
DW, Thirman
M Benzene as a leukemogenic agent: what do cytogenetics tell us? In: Proceedings of the 4th International Symposium on Secondary Leukemia and Leukemogenesis; March 24–26, 2011; Rome, Italy; p. 48.
+
Rader
M Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits. Oncology. 2006; 20:16–21.
+
Reagan
WJ, Handy
V, McKamey
A,
et al. Effects of doxorubicin on the canine erythroid and myeloid progenitor cells and bone marrow microenvironment. Comp Haematol. 1993; 3:96–101.
+
Reagan
WJ, Irizarry-Rovira
A, Poitout-Belissent
F,
et al. Best practices for evaluation of bone marrow in nonclinical toxicity studies. Toxicol Pathol. 2011;39(2):435–448.
+
Reese
JA, Li
X, Hauben
M,
et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood. 2010; 116:2127–2133.
+
Reynolds
VL Applications of emerging technologies in toxicology and safety assessment. Int J Toxicol. 2005; 24:135–137.
+
Ricci-Vitiani
L, Pallini
R, Biffoni
M,
et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010; 468:824–828.
+
Rojas
JC, Aguilar
B, Rodriguez-Maldonado
E,
et al. Pharmacogenetics of oral anticoagulants. Blood Coagul Fibrinolysis. 2005; 16:389–398.
+
Rossi
G, Pelizzari
AM, Bellotti
D,
et al. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. Leukemia. 2000; 14:636–641.
+
Rother
RP, Bell
L, Hillmen
P,
et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005; 293:1653–1662.
+
Roujeau
JC Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005; 209:123–129.
+
Rowe
JM Therapy of secondary leukemia. Leukemia. 2002; 16:748–750.
+
Rowley
JD, Golomb
HM, Vardiman
JW Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood. 1981; 58:759–767.
+
Ryan
DH Examination of the blood. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams Hematology. 7th ed. New York: McGraw-Hill; 2006:11–19.
+
Ryter
SW, Otterbein
LE Carbon monoxide in biology and medicine. Bioessays. 2004; 26:270–280.
+
Sagov
SE March hemoglobinuria treated with rubber insoles: two case reports. J Am Coll Health Assoc. 1970;19:146.
+
Salama
A, Schutz
B, Kiefel
V,
et al. Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. Br J Haematol. 1989; 72:127–132.
+
Sandoval
C, Pui
CH, Bowman
LC,
et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol. 1993;11: 1039–1045.
+
Sanz
MA, Montesinos
P Secondary leukemia in patients treated for acute promyelocytic leukemia. In: Proceedings of the 4th International Symposium on Secondary Leukemia and Leukemogenesis; March 24–26, 2011; Rome, Italy; p. 21.
+
Sato
K, Miyakawa
M, Han
DC,
et al. Graves’ disease with neutropenia and marked splenomegaly: autoimmune neutropenia due to propylthiouracil. J Endocrinol Invest. 1985; 8:551–555.
+
Schmaier
AH, Rojkjaer
R, Shariat-Madar
Z Activation of the plasma kallikrein/kinin system on cells: a revised hypothesis. Thromb Haemost. 1999; 82:226–233.
+
Schneidkraut
MJ, Loegering
DJ Effect of extravascular hemolysis on the RES depression following thermal injury. Exp Mol Pathol. 1984; 40:271–279.
+
Schrijvers
D, Highley
M, De Bruyn
E,
et al. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs. 1999; 10:147–153.
+
Schultz
W About specific sore throat. Dtsch Med Wochenschr. 1922; 48:1495–1496.
+
Sedrakyan
A, Atkins
D, Treasure
T The risk of aprotinin: a conflict of evidence. Lancet. 2006; 367:1376–1377.
+
Sella
R, Flomenbilt
L, Goldstein
I,
et al. Detection of anti-neutrophil antibodies in autoimmune neutropenia of infancy: a multicenter study. Isr Med Assoc J. 2010; 12:91–96.
+
Semerad
CL, Liu
F, Gregory
AD,
et al. G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity. 2002; 17:413–423.
+
Sharma
M, Afrin
F, Satija
N,
et al. Stromal-derived factor-1/CXCR4 signaling: indispensable role in homing and engraftment of hematopoietic stem cells in bone marrow. Stem Cells Dev. 2011;20(6):933–946.
+
Shen
M, Lan
Q, Zhang
L,
et al. Polymorphisms in genes involved in DNA double strand break repair pathway and susceptibility to benzene-induced hematotoxicity. Carcinogenesis. 2006; 27:2083–2089.
+
Shifrine
M, Wilson
FD The Canine as a Biomedical Research Model: Immunological, Hematological and Oncological Aspects. Springfield: US Department of Commerce Technical Information Center; 1980.
+
Shimizu
Y, Kato
H, Schull
WJ,
et al. Studies of the mortality of A-bomb survivors. 9. Mortality, 1950–1985: part 1. Comparison of risk coefficients for site-specific cancer mortality based on the DS86 and T65DR shielded kerma and organ doses. Radiat Res. 1989; 118:502–524.
+
Siebert
WJ, Ayres
RW, Bulling
MT,
et al. Streptokinase morbidity—more common than previously recognised. Aust N Z J Med. 1992; 22:129–133.
+
Slater
K Cytotoxicity tests for high-throughput drug discovery. Curr Opin Biotechnol. 2001; 12:70–74.
+
Smith
MA, Smith
JG, Provan
AB,
et al. The effect of rh-cytokines on the sensitivity of normal human CFU-GM progenitors to Ara-C and on the S-phase activity of light density human bone marrow cells. Leuk Res. 1994; 18:105–110.
+
Stafford
DW The vitamin K cycle. J Thromb Haemost. 2005; 3:1873–1878.
+
Stark
MA, Huo
Y, Burcin
TL,
et al. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity. 2005; 22:285–294.
+
Steinberg
MH Pathophysiologically based drug treatment of sickle cell disease. Trends Pharmacol Sci. 2006; 27:204–210.
+
Stern
A Drug-induced oxidative denaturation in red blood cells. Semin Hematol. 1989; 26:301–306.
+
Stern
SC, Shah
S, Costello
C Probable autoimmune neutropenia induced by fludarabine treatment for chronic lymphocytic leukaemia. Br J Haematol. 1999; 106:836–837.
+
Stoddart
A, McNerney
M, Bartom
E,
et al. Genetic pathways leading to therapy-related myeloid neoplasms. In: Proceedings of the 4th International Symposium on Secondary Leukemia and Leukemogenesis; March 24–26, 2011; Rome, Italy; p. 3.
+
Suber
RL, Kodell
RL The effect of three phlebotomy techniques on hematological and clinical chemical evaluation in Sprague–Dawley rats. Vet Clin Pathol. 1985; 14:23–30.
+
Sundman-Engberg
B, Tidefelt
U, Paul
C Toxicity of cytostatic drugs to normal bone marrow cells in vitro. Cancer Chemother Pharmacol. 1998; 42:17–23.
+
Swerdlow
SH, Campo
E, Harris
NL,
et al. WHO classification of tumours of the hematopoietic and lymphoid tissues. 4th ed. In: WHO Classification of Tumours. Vol. 2. Lyon, France: IACR Press; 2008:439.
+
Szarfman
A, Machado
SG, O’Neill
RT Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Saf. 2002; 25:381–392.
+
Szarfman
A, Talarick
L, Levine
JG Analysis and risk assessment of hematological data from clinical trials. In: Sipes IG MAGA, ed. Comprehensive Toxicology. Oxford: Pergamon Press; 1997:363–379.
+
Tamaoki
J The effects of macrolides on inflammatory cells. Chest. 2004;125:41S–50S.
+
Tannock
IF Experimental chemotherapy and concepts related to the cell cycle. Int J Radiat Biol Relat Stud Phys Chem Med. 1986; 49:335–355.
+
Tavazzi
B, Di
PD, Amorini
AM,
et al. Energy metabolism and lipid peroxidation of human erythrocytes as a function of increased oxidative stress. Eur J Biochem. 2000; 267:684–689.
+
Tesfa
D, Keisu
M, Palmblad
J Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol. 2009; 84:428–434.
+
Thirman
MJ, Larson
RA Therapy-related myeloid leukemia. Hematol Oncol Clin North Am. 1996; 10:293–320.
+
Todd
MD, Ulrich
RG Emerging technologies for accelerated toxicity evaluation of potential drug candidates. Curr Opin Drug Disc Res. 1999; 2:58–68.
+
Turbay
D, Lieberman
J, Alper
CA,
et al. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood. 1997; 89:4167–4174.
+
Uetrecht
J Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions. Crit Rev Toxicol. 1990; 20:213–235.
+
Valagussa
P, Kenda
R, Fossati
F,
et al. Incidence of 2d malignancies in Hodgkin’s-disease (HD) after various forms of treatment [abstract]. Proc Am Soc Clin Oncol. 1979;20:360.
+
Valli
VE, McGrath
JP Comparative leukocyte biology and toxicology. In: Sipes IG MAGA, ed. Comprehensive Toxicology. Oxford: Pergamon Press; 1997:201–215.
+
van den Bemt
PM, Meyboom
RH, Egberts
AC Drug-induced immune thrombocytopenia. Drug Saf. 2004; 27:1243–1252.
+
Van Wijk
R, van Solinge
WW The energy-less blood cell is lost: erythrocyte enzyme abnormalities of glycolysis. Blood. 2005; 106:4034–4042.
+
Vandendries
ER, Drews
RE Drug-associated disease: hematologic dysfunction. Crit Care Clin. 2006; 22:347–355.
+
Varga
J, Uitto
J, Jimenez
SA The cause and pathogenesis of the eosinophilia–myalgia syndrome. Ann Intern Med. 1992; 116:140–147.
+
Varmus
H, Weinberg
RA Genes and the Biology of Cancer. New York: Scientific American Library; 1993.
+
Vermeulen
L, De Sousa
F, Melo
E,
et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010; 12:468–476.
+
Veyradier
A, Meyer
D Thrombotic thrombocytopenic purpura and its diagnosis. J Thromb Haemost. 2005; 3:2420–2427.
+
Vincent
PC Drug-induced aplastic anaemia and agranulocytosis. Incidence and mechanisms. Drugs. 1986; 31:52–63.
+
Vismans
JJ, Briet
E, Meijer
K,
et al. Azathioprine and subacute myelomonocytic leukemia. Acta Med Scand. 1980; 207:315–319.
+
Vogelstein
B, Fearon
ER, Hamilton
SR,
et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319:525–532.
+
Voog
E, Morschhauser
F, Solal-Celigny
P Neutropenia in patients treated with rituximab. N Engl J Med. 2003; 348:2691–2694.
+
Wan
J, Badham
HJ, Winn
L The role of c-MYB in benzene-initiated toxicity. Chem Biol Interact. 2005;153–154:171–178.
+
Warkentin
TE, Greinacher
A Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:311S–337S.
+
Weatherall
D Disorders of globin synthesis in the thalassemias. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams Hematology. 7th ed. New York: McGraw-Hill; 2006:663–666.
+
Weingand
K, Brown
G, Hall
R,
et al. Harmonization of animal clinical pathology testing in toxicity and safety studies. Fundam Appl Toxicol. 1996; 29:198–201.
+
Weiss
DJ, Blauvelt
M, Sykes
J,
et al. Flow cytometric evaluation of canine bone marrow differential cell counts. Vet Clin Pathol. 2000;29: 97–104.
+
West
BC, DeVault
GA
Jr, Clement
JC,
et al. Aplastic anemia associated with parenteral chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine. Rev Infect Dis. 1988; 10:1048–1051.
+
Whichard
ZL, Sarkar
CA, Kimmel
M,
et al. Hematopoiesis and its disorders: a systems biology approach. Blood. 2010;115(12):2339–2347.
+
WHO. World Health Organization Handbook for Reporting Results of Cancer Treatments. Offset Publication No. 48. Geneva: WHO; 1979.
+
Williams
CL, Whitaker
MH The molecular biology of acute myeloid leukemia. Proto-oncogene expression and function in normal and neoplastic myeloid cells. Clin Lab Med. 1990; 10:769–796.
+
Williams
DP, Pirmohamed
M, Naisbitt
DJ,
et al. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol. 2000; 58:207–216.
+
Williams
LH, Udupa
KB, Lipschitz
DA Long-term bone marrow culture as a model for host toxicity: the effect of methotrexate on hematopoiesis and adherent layer function. Exp Hematol. 1988; 16:80–87.
+
Yoo
D, Lessin
LS Drug-associated “bite cell” hemolytic anemia. Am J Med. 1992; 92:243–248.
+
Young
KM, Weiss
L Hematopoiesis: structure–function relationships in bone marrow and spleen. In: Sipes IG, McQueen AC, Gandolfi AJ, eds. Comprehensive Toxicology. Oxford: Pergamon Press; 1997:11–34.
+
Young
NS Acquired aplastic anemia. JAMA. 1999; 282:271–278.
+
Young
NS Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia. Semin Hematol. 2000;37:14.
+
Yunis
JJ, Corzo
D, Salazar
M,
et al. HLA associations in clozapine-induced agranulocytosis. Blood. 1995; 86:1177–1183.
+
Zakarija
A, Bennett
C Drug-induced thrombotic microangiopathy. Semin Thromb Hemost. 2005; 31:681–690.
+
Zhang
X, Liu
F, Chen
X,
et al. Involvement of the immune system in idiosyncratic drug reactions. Drug Metab Pharmacokinet. 2011;26(1):47–59.